Case study: One of the scientists working in the R & D laboratory of a major pharmaceutical company discovers that one of the company’s best selling veterinary…
List the realistic options open to the CEO and weigh the merits and demerits of each before arriving at a reasoned choice.
Common trap: Many answers jump straight to doing it free, ignoring shareholders. The best answers present several options, evaluate each honestly, and show how partnerships and CSR can make a humane choice financially responsible.
SyllabusEthical concerns and dilemmas in government and private institutions; laws, rules, regulations and conscience as sources of ethical guidance; accountability and ethical governance; corporate governance.
The case
One of the scientists working in the R & D laboratory of a major pharmaceutical company discovers that one of the company’s best selling veterinary drugs, B has the potential to cure a currently incurable liver disease that is prevalent in tribal areas. However, developing a variant of the drug suitable for human beings entailed a lot of research and development having a huge expenditure to the extent of ₹ 50 crores. It was unlikely that the company would recover the costs as the disease was rampant only in poverty-stricken area having very little market otherwise. If you were the CEO, then— (a) identify the various actions that you could take; (b) evaluate the pros and cons of each of your actions.
Model answer
20 marks · 250-word limitThe dilemma is between shareholder value and the moral pull of a cure for poor tribal patients. Milton Friedman argued in 1970 that business's social responsibility is to increase profits; stakeholder thinking and Gandhi's idea of trusteeship ask that wealth also serve those who need it most.
- Fiduciary duty to investors
- Little market, costs unlikely to be recovered
- Funds diverted from profitable R&D
- Incurable disease among the poorest
- Company holds unique knowledge
- Reputation, trust, long-term licence to operate
(a) Actions available to the CEO
- Shelve the research: Treat it as commercially unviable and continue only the veterinary product.
- Develop it alone as a social project: Fund the ₹50 crore from internal resources and supply the drug at cost or free.
- Fund through CSR: Section 135 of the Companies Act 2013, in force since April 2014, requires qualifying companies to spend 2% of average net profit; promoting health care is a Schedule VII activity.
- Partnerships: Co-develop with ICMR, government health programmes, global health foundations or non-profit drug developers to share cost and risk, with the state buying the drug for tribal areas.
- Share or license the knowledge: Pass the data and rights to a public or non-profit body if the company cannot carry the project.
(b) Pros and cons of each action
| Action | Pros | Cons |
|---|---|---|
| Shelve | Protects profits; avoids risk | Abandons a curable suffering; reputational and moral cost; knowledge wasted |
| Go it alone | Full control; strong goodwill | Heavy burden on shareholders; may hurt other R&D |
| CSR route | Lawful, board-approved use of mandated funds; brand trust | CSR budget may be too small; CSR Rules 2014 exclude normal-course-of-business activity, so CSR suits free supply and screening more than core R&D |
| Partnerships | Cost and risk shared; government reach to tribal areas | Slower decisions; sharing of rights and credit |
| License or share | Cure still reaches patients; low cost | Loss of potential future revenue and control |
Recommended course
- Hybrid path: Combine CSR funds with a partnership with ICMR and state governments, with an advance purchase commitment for tribal health programmes.
- Ethical trials: Follow the Drugs and Cosmetics Act 1940 and ICMR ethical guidelines, with genuine informed consent in local languages, as tribal patients are a vulnerable group.
- Precedent: In the late 1980s Merck pledged to donate ivermectin, first sold as a veterinary drug, to fight river blindness; its discoverers shared the 2015 Nobel Prize in Medicine.
A company that turns its own discovery into a cure for the forgotten poor earns trust no advertisement can buy. Through CSR, partnerships and fair trials, the CEO can honour both fiduciary duty and conscience, treating tribal patients as ends in themselves, as Kant would demand.
Read more — sources
- OfficialCompanies Act, 2013 — Section 135 and Schedule VII; Companies (CSR Policy) Rules, 2014
- OfficialICMR, Ethical Guidelines for Biomedical Research on Human Participants (2006)
- OfficialDrugs and Cosmetics Act, 1940 and Rules (Schedule Y, clinical trials)
- BookMilton Friedman, The Social Responsibility of Business Is to Increase Its Profits, New York Times Magazine (1970)
Related questions from earlier years
More from GS Paper 4 (Ethics) 2015
Model answer by the EdiShorts editorial team. It is one well-argued treatment of the question, written to the official word limit — not an official UPSC answer key.